Genmab A/S Stock Forecast for 2023 - 2025 - 2030

Updated on 12/07/2023

Stock Rating
16
Price Target
kr2.70k
Consensus
Outperform
Upside
21.35%
Analysts
3
Stock Rating
16
Upside
21.35%
Analysts
3
Price Target
kr2.70k

Genmab A/S Stock Forecast and Price Target

If the average 2023 price target of kr2700.00 recently set by three prominent experts for Genmab A/S is met, there would be a potential upside of approximately 21.35% from the last closing price in December, 2023. The high estimate is kr3320.00, and the low is kr2000.00. If you're looking to buy Genmab A/S stock, you may also want to check out its rivals.

kr2.70k

21.35% Upside

Outperform
Outperform

Genmab A/S Fair Value Forecast for 2023 - 2025 - 2030

In the last three years, Genmab A/S's Price has grown, rising from kr1342.48 to kr3299.99 – a growth of 145.81%. According to 22 major analysts, Genmab A/S's Fair Value will fall by 10.57% in the next year, reaching kr2951.25. For the next eight years, the forecast is for Fair Value to grow by 217.92%.

2023 Fair Value Forecast
kr2.95k
2024 Fair Value Forecast
kr3.34k
2025 Fair Value Forecast
kr4.57k
2026 Fair Value Forecast
kr6.13k
2027 Fair Value Forecast
kr7.69k
2028 Fair Value Forecast
kr10.19k
2029 Fair Value Forecast
kr11.75k
2030 Fair Value Forecast
kr10.49k
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
ABBV Stock Forecast AbbVie Outperform 10
$146.38 Buy/Sell $167.35 14.09%
NOVN Stock Forecast Novartis Outperform 9
CHF84.89 Buy/Sell CHF103.75 21.05%
AMGN Stock Forecast Amgen Inc Outperform 7
$269.35 Buy/Sell $276.06 6.55%
BMY Stock Forecast Bristol-Myers Squibb Co Outperform 2
$49.88 Buy/Sell $64.13 23.30%
MRK Stock Forecast Merck KGaA Buy 17
140.75€ Buy/Sell 204.63€ 32.50%

Genmab A/S Revenue Forecast for 2023 - 2025 - 2030

In the last three years, Genmab A/S's Revenue has grown, rising from kr5.37B to kr14.60B – a growth of 171.99%. In the next year, analysts believe that Revenue will reach kr16.39B – an increase of 12.29%. For the next eight years, the forecast is for Revenue to grow by 161.35%.

2023 Rev Forecast
kr16.39B
2024 Rev Forecast
kr19.31B
2025 Rev Forecast
kr22.93B
2026 Rev Forecast
kr26.99B
2027 Rev Forecast
kr31.42B
2028 Rev Forecast
kr38.16B
2029 Rev Forecast
kr41.13B
2030 Rev Forecast
kr38.14B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
4502 Stock Forecast Takeda Pharmaceutical Company Outperform 16
¥4.14k Buy/Sell ¥0.00 13.44%
BAYN Stock Forecast Bayer Outperform 7
32.39€ Buy/Sell 55.86€ 38.93%
BIIB Stock Forecast Biogen Inc Outperform 11
$233.87 Buy/Sell $322.44 32.98%

Genmab A/S Dividend per Share Forecast for 2023 - 2025 - 2030

2023 DPS Forecast
kr0.00
2024 DPS Forecast
kr0.00
2025 DPS Forecast
kr0.00
2026 DPS Forecast
kr0.00
2027 DPS Forecast
kr0.00
2028 DPS Forecast
kr0.00
2029 DPS Forecast
kr0.00
2030 DPS Forecast
kr0.00
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
ARGX Stock Forecast argenx Outperform 4
427.00€ Buy/Sell 0.00€ 22.48%
TEVA Stock Forecast Teva Pharmaceutical Industries Outperform 12
$9.83 Buy/Sell $12.04 9.36%
REC Stock Forecast Recordati Industria Chimica e ... Outperform 18
46.24€ Buy/Sell 49.03€ 0.56%

Genmab A/S Free Cash Flow Forecast for 2023 - 2025 - 2030

In the last three years, Genmab A/S's Free Cash Flow has grown by 188.29%, rising from kr1.25B to kr3.60B. For the next year, analysts predict that Free Cash Flow will reach kr4.98B – an increase of 38.65%. Over the next eight years, experts believe that Genmab A/S's Free Cash Flow will grow at a rate of 263.42%.

2023 FCF Forecast
kr4.98B
2024 FCF Forecast
kr5.38B
2025 FCF Forecast
kr7.15B
2026 FCF Forecast
kr9.54B
2027 FCF Forecast
kr10.45B
2028 FCF Forecast
kr12.09B
2029 FCF Forecast
kr12.61B
2030 FCF Forecast
kr13.07B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
ORNBV Stock Forecast Orion Oyj Outperform 14
36.11€ Buy/Sell 34.70€ 20.47%
HIK Stock Forecast Hikma Pharmaceuticals PLC Outperform 18
£18.03 Buy/Sell £28.13 54.02%
ALK B Stock Forecast ALK-Abelló A/S Outperform 13
kr93.15 Buy/Sell kr117.80 22.92%

Genmab A/S Net Income Forecast for 2023 - 2025 - 2030

Genmab A/S's Net Income has seen impressive growth In the last three years, rising from kr2.17B to kr5.52B – a growth of 154.94%. According to 21 analysts, Genmab A/S's Net Income will fall by 11.79% in the next year, reaching kr4.87B. For the next eight years, the forecast is for Net Income to grow by 264.56%.

2023 NI Forecast
kr4.87B
2024 NI Forecast
kr5.58B
2025 NI Forecast
kr7.57B
2026 NI Forecast
kr10.35B
2027 NI Forecast
kr12.98B
2028 NI Forecast
kr18.04B
2029 NI Forecast
kr20.64B
2030 NI Forecast
kr20.13B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
INDV Stock Forecast Indivior PLC Buy 14
£11.85 Buy/Sell £3.79 144.73%
TGTX Stock Forecast TG Therapeutics Outperform 9
$16.45 Buy/Sell $26.83 45.90%
ALM Stock Forecast Almirall Outperform 16
8.51€ Buy/Sell 11.47€ 32.20%

Genmab A/S EBITDA Forecast for 2023 - 2025 - 2030

In the last three years, Genmab A/S's EBITDA has grown, moving from kr2.78B to kr6.72B – an increase of 141.95%. 15 analysts predict Genmab A/S's EBITDA will decrease by 14.04% in the next year, reaching kr5.78B. Looking ahead to eight years, experts forecast that EBITDA will grow by 194.52%.

2023 EBITDA Forecast
kr5.78B
2024 EBITDA Forecast
kr6.97B
2025 EBITDA Forecast
kr9.33B
2026 EBITDA Forecast
kr11.86B
2027 EBITDA Forecast
kr14.17B
2028 EBITDA Forecast
kr15.90B
2029 EBITDA Forecast
kr17.88B
2030 EBITDA Forecast
kr19.79B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
MRUS Stock Forecast Merus N.V. Buy 6
$24.78 Buy/Sell $0.00 75.54%
XNCR Stock Forecast Xencor Buy 6
$19.26 Buy/Sell $39.71 89.51%
FAE Stock Forecast Faes Farma Hold 18
3.22€ Buy/Sell 3.90€ 20.50%

Genmab A/S EBIT Forecast for 2023 - 2025 - 2030

In the last three years, Genmab A/S's EBIT has seen an increase, rising from kr2.64B to kr6.40B. This represents a growth of 142.42%. For the following year, the 23 analysts predict that Genmab A/S's EBIT will drop by 15.02%, reaching kr5.43B. Over the next eight years, experts predict that Genmab A/S's EBIT will grow at a rate of 205.53%.

2023 EBIT Forecast
kr5.43B
2024 EBIT Forecast
kr6.66B
2025 EBIT Forecast
kr8.99B
2026 EBIT Forecast
kr11.87B
2027 EBIT Forecast
kr14.90B
2028 EBIT Forecast
kr19.97B
2029 EBIT Forecast
kr21.75B
2030 EBIT Forecast
kr19.54B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
COPN Stock Forecast Cosmo Pharmaceuticals N.V. Buy 12
CHF43.55 Buy/Sell CHF0.00 62.62%
ZEAL Stock Forecast Zealand Pharma A/S Buy 8
kr350.60 Buy/Sell kr241.83 11.52%
PHM Stock Forecast Pharma Mar Outperform 13
39.08€ Buy/Sell 80.40€ 26.66%

Genmab A/S EPS Price Prediction Forecast for 2023 - 2025 - 2030

In the last three years, Genmab A/S's EPS has grown, rising from kr34.03 to kr83.65 – a growth of 145.81%. According to 22 major analysts, Genmab A/S's EPS will fall by 10.57% in the next year, reaching kr74.81. For the next eight years, the forecast is for EPS to grow by 217.92%.

2023 EPS Forecast
kr74.81
2024 EPS Forecast
kr84.74
2025 EPS Forecast
kr115.75
2026 EPS Forecast
kr155.27
2027 EPS Forecast
kr194.89
2028 EPS Forecast
kr258.41
2029 EPS Forecast
kr297.75
2030 EPS Forecast
kr265.94
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
BSLN Stock Forecast Basilea Pharmaceutica Outperform 6
CHF34.45 Buy/Sell CHF87.60 123.51%
MOLN Stock Forecast Molecular Partners Outperform 4
CHF3.79 Buy/Sell CHF27.57 150.66%
DBV Stock Forecast DBV Technologies Outperform 5
1.53€ Buy/Sell 12.23€ 83.66%